



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/667,216
				Filing Date	September 19, 2003
				First Named Inventor	Shaker A. Mousa
				Art Unit	1623
Sheet	1	of	4	Examiner Name	Fe-De Assigned D. KHARE
				Attorney Docket Number	2747/1021

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
AM	1	US-5,092,885	03/03/1992	Yamada et al.	
	2	US-5,112,946	05/12/1992	Maione	
	3	US-5,192,744	03/09/1993	Bouck et al.	
	4	US-5,202,352	04/13/1993	Okada et al.	
AM	5	US-5,639,725	06/17/1997	O'Reilly et al.	
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ Number ⁴ Kind Code ² (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AM	6	Braswell, E., "Heparin: Molecular Weight and Degradation Studies," <i>Biochim. Biophys. Acta</i> 158:103-116 (1968)	
	7	Kosakai et al., "Isolation and Characterization of Sulfated Disaccharides from the Deamination Products of Porcine Heparin (α -Heparin) and Whale Heparin (ω -Heparin), and a Comparison of the Deamination Products," <i>J. Biochem.</i> 83:1567-1575 (1978)	
AM	8	Fransson, et al., "Relationship Between Anticoagulant Activity of Heparin and Susceptibility to Periodate Oxidation," <i>FEBS Letters</i> 97:119-123 (1979)	

Examiner Signature	<i>AM</i>	Date Considered	6/17/05
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/667,216
				Filing Date	September 19, 2003
				First Named Inventor	Shaker A. Mousa
				Group Art Unit	1623
				Examiner Name	To Be Assigned
Sheet	2	of	4	Attorney Docket Number	2747/1021

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm	9	Fujita et al., "Improvement of Treadmill Capacity and Collateral Circulation as a Result of Exercise with Heparin Pretreatment in Patients with Effort Angina," <i>Circulation</i> 77:1022-1029 (1988)	
	10	Rastinejad et al., "Regulation of the Activity of a New Inhibitor of Angiogenesis by a Cancer Suppressor Gene," <i>Cell</i> 56:345-355 (1989)	
	11	Moses et al., "Identification of an Inhibitor of Neovascularization from Cartilage," <i>Science</i> 248:1408-1410 (1990)	
	12	Blood et al., "Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis," <i>Biochim. Biophys. Acta</i> 1032:89-118 (1990)	
	13	Oikawa et al., "Angiogenic Factor of a Rat Mammary Tumor Cell Line (RMT-1) (I). Secretion of Two Distinct Angiogenic Factors into Serum-Free Conditioned Medium by RMT-1 Cells," <i>Cancer Letters</i> 59:57-66 (1991)	
	14	Buckley et al., "Enoxaparin: A Review of its Pharmacology and Clinical Applications in the Prevention and Treatment of Thromboembolic Disorders," <i>Drugs</i> 44:465-497 (1992)	
	15	Clapp et al., "The 16-Kilodalton N-Terminal Fragment of Human Prolactin Is a Potent Inhibitor of Angiogenesis," <i>Endocrinology</i> 133:1292-1299 (1993)	
	16	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases," <i>Cell</i> 79:315-328 (1994)	
	17	Chen et al., "A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors," <i>Cancer Research</i> 55:4230-4233 (1995)	
	18	Schnaper et al., "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>Journal of Cellular Physiology</i> 165:107-118 (1995)	
an	19	Larnkjaer et al., "Isolation and Characterization of Hexasaccharides Derived from Heparin. Analysis by HPLC and Elucidation of Structure by ¹ H NMR," <i>Carbohydrate Research</i> 266:37-52 (1995)	

Examiner Signature	<i>dkw</i>	Date Considered	6/17/05
--------------------	------------	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/667,216
				Filing Date	September 19, 2003
				First Named Inventor	Shaker A. Mousa
				Group Art Unit	1623
Examiner Name	To Be Assigned				
Sheet	3	of	4	Attorney Docket Number	2747/1021

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dl	20	Strieter et al., "Interferon γ -Inducible Protein 10 (IP-10), a Member of the C-X-C Chemokine Family, is an Inhibitor of Angiogenesis," <i>Biochemical and Biophysical Research Communications</i> 210:51-57 (1995)	
	21	Angiolillo et al., "Human Interferon-inducible Protein 10 is a Potent Inhibitor of Angiogenesis In Vivo," <i>J. Experimental Medicine</i> 182:155-162 (1995)	
	22	Parangi et al., "Antiangiogenic Therapy of Transgenic Mice Impairs <i>de novo</i> Tumor Growth," <i>Proc. Natl. Acad. Sci. USA</i> 93:2002-2007 (1996)	
	23	Risau, "Mechanisms of Angiogenesis," <i>Nature</i> 386:671-674 (1997)	
	24	Mulloy et al., "Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography," <i>Thrombosis and Haemostasis</i> 4:668-674 (1997)	
	25	Dickinson et al., "Enoxaparin Increases the Incidence of Postoperative Intracranial Hemorrhage when Initiated Preoperatively for Deep Venous Thrombosis Prophylaxis in Patients with Brain Tumors," <i>Neurosurgery</i> 43:1074-1081 (1998)	
	26	Linhardt et al., "Production and Chemical Processing of Low Molecular Weight Heparins," <i>Seminars in Thrombosis and Haemostasis</i> 25:5-16 (1999)	
	27	Kosir et al., "Degradation of Basement Membrane by Prostate Tumor Heparanase," <i>Journal of Surgical Research</i> 81:42-47 (1999)	
	28	Kakkar et al., "Antithrombotic Therapy in Cancer," <i>BMJ</i> 318:1571-1572 (1999)	
	29	Hettiarachchi et al., "Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread," <i>Thrombosis and Haemostasis</i> 82:947-952 (1999)	
dl	30	Mousa et al., "Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of Thromboelastography," <i>Arterioscler. Thromb. Vasc. Biol.</i> 20:1162-1167 (2000)	

Examiner Signature	<i>dkhan</i>	Date Considered	6/17/05
--------------------	--------------	-----------------	---------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/667,216
				Filing Date	September 19, 2003
				First Named Inventor	Shaker A. Mousa
				Group Art Unit	1623
				Examiner Name	To Be Assigned
Sheet	4	of	4	Attorney Docket Number	2747/1021

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm	31	Arkel, "Thrombosis and Cancer," <i>Seminars in Oncology</i> 27:362-374 (2000)	
	32	Zacharski et al., "Low-Molecular-Weight Heparin and Cancer," <i>Seminars in Thrombosis and Hemostasis</i> 26:69-77 (2000)	
	33	Eriksson et al., "Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism After Hip-Fracture Surgery," <i>N. Engl. J. Med.</i> 345:1298-1304 (2001)	
	34	Smorenburg et al., "The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies," <i>Pharmacological Reviews</i> 53:93-105 (2001)	
	35	Mousa et al., "Comparison of the Effect of Different Platelet GPIIb/IIIa Antagonists on the Dynamics of Platelet/Fibrin-Mediated Clot Strength Induced Using Thromboelastography," <i>Thrombosis Research</i> 104:49-56 (2001)	
	36	Morita et al., "High Affinity Binding of Heparin by Necrotic Tumour Cells Neutralises Anticoagulant Activity," <i>Thromb. Haemost.</i> 86:616-622 (2001)	
cm	37	Prandoni, "Heparins and Venous Thromboembolism: Current Practice and Future Directions," <i>Thromb. Haemost.</i> 86:488-498 (2001)	

Examiner Signature	<i>d. K. Hume</i>	Date Considered	6/17/05
--------------------	-------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.